Similar Items: Prognostic Value of Next‐Generation Flow Cytometry Versus Dual‐Tracer PET/CT for Minimal Residual Disease Assessment in Multiple Myeloma
- Serum ATIC Expression as a Novel Diagnostic and Prognostic Biomarker in Multiple Myeloma Patients
- Potential of oncolytic viruses in the treatment of multiple myeloma
- The Role of Genomics in the Development and Treatment of Multiple Myeloma: Understanding the Challenges and Opportunities
- Defining High-Risk Disease Biology in Multiple Myeloma: A Narrative Review
- IMMPACT-MM: Insights into Multiple Myeloma Patient Outcomes following Early-Line Cilta-cel Treatment
- Synergistic Antitumor Activity of HAT Inhibitor A485 and XPO1 Inhibitor KPT8602 in Multiple Myeloma